Clinical Trials
Pharm-Olam is proud to have contributed to the execution and completion of Cablivi ivotal Phase III study
Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market...
Clinical Trials
REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314
REGENXBIO Inc. a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced updated results from the ongoing Phase I study of RGX-314 for the treatment...
Clinical Trials
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
Quotient Sciences, a leading drug development services organization, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million...
Clinical Trials
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple...
Clinical Trials
GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer
GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, announces that it has dosed the first patient in its Phase 2 clinical trial - of GM102 single...
Clinical Trials
Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke
Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of low-dose tissue plasminogen activator (tPA) and HisproUK (TSI’s mutant prourokinase ) in patients who...
Clinical Trials
CRF Health Partners Innovative US Biotech with TrialMax® eCOA Solution for Phase III Prostate Oncology Study
CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that its TrialMax® Slate solution has been selected by a US biotech company for a global Phase III prostate cancer study. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
